The National Institute for Health and Care Excellence (NICE) said in draft final guidance that it estimates some 180,000 people could benefit from the new treatment.
Tag Archive for: supply chain
Upcoming regulatory changes surrounding the use of perfluoroalkyl and polyfluoroalkyl substances (PFAS) have been making headlines across the globe. As the United States and European Union continue to move toward banning and limiting the use of PFAS products, the pharmaceutical industry, much like others, must address the mounting risks related to this family of chemicals.
The struggle to satisfy demand means Novo could lose out on market share to a string of competitors working on weight-loss therapies similar to Wegovy, vying for a slice of a market estimated to be worth as much as $100 billion by the end of the decade.
Granules faced a cyber security attack that caused major disruptions in its operations, affecting its IT assets. A ransomware group has claimed responsibility, the company said.
Today the company warned of a steeper earnings decline due to a slump in demand for materials used to produce pharmaceuticals and semiconductors, as its high-tech niche markets get drawn into a wider downturn.
Siemens Healthineers lowered its profit margin outlook for Varian due to “temporary challenges in outbound logistics” at its U.S. maker of devices and software for treating cancer to 14-15% from a previous 16-18%.
The legislative effort comes after House Republicans denied the Democrats’ push to include similar provisions in the Pandemic and All Hazards Preparedness Act (PAHPA). In a statement earlier this month, House Democrats called it “unconscionable” that their GOP colleagues decided to reject “five commonsense proposals” seeking to address the current drug shortage crisis.
Oncologists are deeply concerned about the limited alternatives to two critical chemotherapy drugs, which are not as effective in treating certain types of cancer and can even be more toxic. This scarcity of backup therapies poses particularly troubling prospects for patients with ovarian, testicular, breast, lung and head and neck cancers.
Following two BLA rejections for its Humira biosimilar, Alvotech is expanding its partnership with Teva Pharmaceuticals, which will enable the latter to have greater involvement with quality and control.
“To have equitable distribution of the products and ensure availability to those in most need, as well as to avoid hoarding, Pfizer has put the inventory of many products on strict allocation,” stated FDA Commissioner Robert Califf, M.D.
